Chendi Li,Mohammed Usman Syed,Anahita Nimbalkar et al. Chendi Li et al.

The efficacy of molecularly targeted therapies may be limited by co-occurring mutations within a tumor. Conversely, these alterations may confer collateral vulnerabilities that can be therapeutically leveraged. KRAS-mutant lung cancers are ...

Xiaojie Tong,Tong Shen,Song Li et al. Xiaojie Tong et al.

CDK4/6 is the candidate therapeutic target for KRAS-mutant NSCLC. However, its frequent primary and acquired resistance limits its potential clinical application. Recently it had been shown that BRD4 up-regulation induced conferred resistan...

Shahad Khalid Hussein Hussein,Olga Tcacenco Shahad Khalid Hussein Hussein

Histiocytic sarcoma (HS) is a rare and aggressive malignant neoplasm from histiocytic cells. This case report describes a 52-year-old male with HS involving multiple abdominal sites, diagnosed through imaging, histopathology, and immunohist...

Mohammad Rezazadeh,Ahmadreza Kheradpishe,Amirreza Kamyabi et al. Mohammad Rezazadeh et al.

Early-onset colorectal cancer (EO-CRC), defined as colorectal adenocarcinoma diagnosed before age 50, is increasing globally, with distinct clinicopathologic and molecular features compared to adult-onset disease. While risk factors such as...

Yurong Xiang,Qiang Liu,Kang Liu et al. Yurong Xiang et al.

Multi-drug combination therapy is one of the most effective strategies for the treatment of drug-resistant and advanced tumors. Modern nanodrug delivery systems are crucial for multi-drug combination therapy and gene therapy. However, resea...

Yaojin Zhu,Zhenqian Chen,Guoyuan Wu et al. Yaojin Zhu et al.

Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations are a common type of oncogenic mutation, widely observed in various cancers. The trafficking chaperone PDE6D (or PDEδ) has been proposed as an alternative target for KRAS, which...

Lingyu Li,Qingying Liu,Yuyu Shao et al. Lingyu Li et al.

KRAS mutation results in higher proliferation rates and miserable prognosis of cancers. Targeting the interaction between KRAS and PDE6D provided an alternative strategy to overcome KRAS-mutant pancreatic cancers. Gaudichaudione H (GH) is a...

Nurullah Ilhan,Faysal Dane,Erdem Goker et al. Nurullah Ilhan et al.

Background and Objectives: KRAS genes are among the most prominent oncogenes that trigger tumor formation in colorectal cancer (CRC) and serve as predictive biomarkers for resistance to anti-EGFR therapies in metastatic colorectal cancer (m...

Di Kang,Jing Li,Yangyang Li et al. Di Kang et al.

The prognostic significance of KRAS and BRAF mutations is well-established in metastatic colorectal cancer (CRC) but remains uncertain in early-stage tumors. This study retrospectively analyzed 47 stage II/III CRC patients undergoing curati...

Hashim Talib Hashim,Ahmed Qasim Mohammed Alhatemi,Tehreem Fatima et al. Hashim Talib Hashim et al.

Background: Pancreatic cancer is one of the main causes of cancer-related deaths, especially pancreatic ductal adenocarcinoma, and it's characterized by a poor prognosis. The KRAS gene mutation is prevalent in about 85% o...